LAMC2 is a potential prognostic biomarker for cholangiocarcinoma

Ong,Khaa Hoo; Hsieh,Yao-Yu; Lai,Hong-Yue; Sun,Ding-Ping; Chen,Tzu-Ju; Huang,Steven Kuan‑Hua; Tian,Yu-Feng; Chou,Chia-Lin; Shiue,Yow-Ling; Wu,Hung-Chang; Chan,Ti-Chun; Tsai,Hsin-Hwa; Li,Chien-Feng; Kuo,Yu-Hsuan

doi:10.3892/ol.2023.14120

LAMC2 is a potential prognostic biomarker for cholangiocarcinoma

Authors:
- Khaa Hoo Ong
- Yao-Yu Hsieh
- Hong-Yue Lai
- Ding-Ping Sun
- Tzu-Ju Chen
- Steven Kuan‑Hua Huang
- Yu-Feng Tian
- Chia-Lin Chou
- Yow-Ling Shiue
- Hung-Chang Wu
- Ti-Chun Chan
- Hsin-Hwa Tsai
- Chien-Feng Li
- Yu-Hsuan Kuo
View Affiliations

Affiliations: Department of Surgery, Division of Gastroenterology and General Surgery, Chi Mei Medical Center, Tainan 710, Taiwan, R.O.C., Division of Hematology and Oncology, Taipei Medical University Shuang Ho Hospital, New Taipei 23561, Taiwan, R.O.C., Department of Pharmacology, School of Medicine, College of Medicine, China Medical University, Taichung 404, Taiwan, R.O.C., Department of Medical Technology, Chung Hwa University of Medical Technology, Tainan 717, Taiwan, R.O.C., Department of Surgery, Division of Urology, Chi Mei Medical Center, Tainan 710, Taiwan, R.O.C., Department of Surgery, Division of Colon and Rectal Surgery, Chi Mei Medical Center, Tainan 710, Taiwan, R.O.C., Institute of Biomedical Sciences, National Sun Yat‑sen University, Kaohsiung 804, Taiwan, R.O.C., Department of Internal Medicine, Division of Hematology and Oncology, Chi‑Mei Medical Center, Tainan 71004, Taiwan, R.O.C., Department of Medical Research, Chi Mei Medical Center, Tainan 710, Taiwan, R.O.C., Department of Laboratory Medicine, China Medical University Hospital, Taichung 404, Taiwan, R.O.C., Institute of Precision Medicine, National Sun Yat‑sen University, Kaohsiung 804, Taiwan, R.O.C.
Published online on: October 30, 2023 https://doi.org/10.3892/ol.2023.14120
Article Number: 533
Copyright: © Ong et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cholangiocarcinoma is a common malignancy with increasing incidence worldwide. Most patients are diagnosed at the advanced stage with poor survival rate. Laminin subunit γ2 (LAMC2) is a heparin binding‑associated gene involved in tumorigenesis and has been implicated in the prognosis of various types of cancers. However, it is unclear whether expression of LAMC2 is associated with the clinical outcome of patients with cholangiocarcinoma. In the present study, the role and prognostic value of LAMC2 expression in patients with cholangiocarcinoma was investigated. Clinical information and pathological characteristics were analyzed and the association between LAMC2 expression and clinical characteristics, pathological findings and patient outcomes, including metastasis‑free and disease‑specific survival, were investigated. Data from 182 patients with cholangiocarcinoma were evaluated. High LAMC2 expression was associated with higher tumor stage (P<0.001), large duct type (P=0.024) and poor histological grade (P=0.002). Kaplan‑Meier analysis showed high LAMC2 expression was associated with lower overall (P=0.003), disease‑specific (P=0.0025), local recurrence‑free (P<0.0001) and metastasis‑free survival (P<0.0001). Moreover, multivariate analysis demonstrated that increased LAMC2 expression was a significant predictive risk factor for overall [hazard ratio (HR) 1.713; P=0.034], disease‑specific (HR 2.011; P=0.039), local recurrence‑free (HR 2.721; P<0.001) and metastasis‑free survival (HR 3.117; P<0.001). Gene enrichment analysis using Gene Ontology showed that terms associated with LAMC2 upregulation were ‘regulation of platelet‑derived growth factor receptor‑βsignaling pathway’ and ‘platelet‑derived growth factor receptor‑β signaling pathway’. The present study indicated that LAMC2 was upregulated in cholangiocarcinoma tumor tissue and had an inverse association with overall, disease‑specific, local recurrence‑free and metastasis‑free survival in patients with cholangiocarcinoma. These results suggested that LAMC2 may serve as a potential biomarker for cholangiocarcinoma.

View Figures

View References

1	Banales JM, Marin JJG, Lamarca A, Rodrigues PM, Khan SA, Roberts LR, Cardinale V, Carpino G, Andersen JB, Braconi C, et al: Cholangiocarcinoma 2020: The next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol. 17:557–588. 2020. View Article : Google Scholar : PubMed/NCBI
2	Neuzillet C, Emery C, Teissier C, Bouée S and Lièvre A: Patient healthcare trajectories of intrahepatic cholangiocarcinoma in France: A nationwide retrospective analysis. Lancet Reg Health Eur. 15:1003242022. View Article : Google Scholar : PubMed/NCBI
3	Khuntikeo N, Titapun A, Loilome W, Yongvanit P, Thinkhamrop B, Chamadol N, Boonmars T, Nethanomsak T, Andrews RH, Petney TN and Sithithaworn P: Current perspectives on opisthorchiasis control and cholangiocarcinoma detection in Southeast Asia. Front Med (Lausanne). 5:1172018. View Article : Google Scholar : PubMed/NCBI
4	Arunsan P, Ittiprasert W, Smout MJ, Cochran CJ, Mann VH, Chaiyadet S, Karinshak SE, Sripa B, Young ND, Sotillo J, et al: Programmed knockout mutation of liver fluke granulin attenuates virulence of infection-induced hepatobiliary morbidity. Elife. 8:e414632019. View Article : Google Scholar : PubMed/NCBI
5	Hoyos S, Navas MC, Restrepo JC and Botero RC: Current controversies in cholangiocarcinoma. Biochim Biophys Acta Mol Basis Dis. 1864:1461–1467. 2018. View Article : Google Scholar : PubMed/NCBI
6	Rizvi S, Khan SA, Hallemeier CL, Kelley RK and Gores GJ: Cholangiocarcinoma-evolving concepts and therapeutic strategies. Nat Rev Clin Oncol. 15:95–111. 2018. View Article : Google Scholar : PubMed/NCBI
7	Brindley PJ, Bachini M, Ilyas SI, Khan SA, Loukas A, Sirica AE, The BT, Wongkham S and Gores GJ: Cholangiocarcinoma. Nat Rev Dis Primers. 7:652021. View Article : Google Scholar : PubMed/NCBI
8	Ljubimova JY, Fujita M, Khazenzon NM, Ljubimov AV and Black KL: Changes in laminin isoforms associated with brain tumor invasion and angiogenesis. Front Biosci. 11:81–88. 2006. View Article : Google Scholar : PubMed/NCBI
9	Garg M, Braunstein G and Koeffler HP: LAMC2 as a therapeutic target for cancers. Expert Opin Ther Targets. 18:979–982. 2014. View Article : Google Scholar : PubMed/NCBI
10	Moon YW, Rao G, Kim JJ, Shim HS, Park KS, An SS, Kim B, Steeg PS, Sarfaraz S, Changwoo Lee L, et al: LAMC2 enhances the metastatic potential of lung adenocarcinoma. Cell Death Differ. 22:1341–1352. 2015. View Article : Google Scholar : PubMed/NCBI
11	Huang D, Du C, Ji D, Xi J and Gu J: Overexpression of LAMC2 predicts poor prognosis in colorectal cancer patients and promotes cancer cell proliferation, migration, and invasion. Tumour Biol. 39:10104283177058492017. View Article : Google Scholar : PubMed/NCBI
12	Okada Y, Takahashi N, Takayama T and Goel A: LAMC2 promotes cancer progression and gemcitabine resistance through modulation of EMT and ATP-binding cassette transporters in pancreatic ductal adenocarcinoma. Carcinogenesis. 42:546–556. 2021. View Article : Google Scholar : PubMed/NCBI
13	Takahashi S, Hasebe T, Oda T, Sasaki S, Kinoshita T, Konishi M, Ochiai T and Ochiai A: Cytoplasmic expression of laminin gamma2 chain correlates with postoperative hepatic metastasis and poor prognosis in patients with pancreatic ductal adenocarcinoma. Cancer. 94:1894–1901. 2002. View Article : Google Scholar : PubMed/NCBI
14	Yang JL, Wang CCN, Cai JH, Chou CY, Lin YC and Hung CC: Identification of GSN and LAMC2 as key prognostic genes of bladder cancer by integrated bioinformatics analysis. Cancers (Basel). 12:18092020. View Article : Google Scholar : PubMed/NCBI
15	Guess CM and Quaranta V: Defining the role of laminin-332 in carcinoma. Matrix Biol. 28:445–455. 2009. View Article : Google Scholar : PubMed/NCBI
16	Edge SB and Compton CC: The American joint committee on cancer: The 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010. View Article : Google Scholar : PubMed/NCBI
17	Khan SA, Tavolari S and Brandi G: Cholangiocarcinoma: Epidemiology and risk factors. Liver Int. 39 (Suppl 1):S19–S31. 2019. View Article : Google Scholar
18	Ceci L, Zhou T, Lenci I, Meadows V, Kennedy L, Li P, Ekser B, Milana M, Zhang W, Wu C, et al: Molecular mechanisms linking risk factors to cholangiocarcinoma development. Cancers (Basel). 14:14422022. View Article : Google Scholar : PubMed/NCBI
19	Baidoun F, Sarmini MT, Merjaneh Z and Moustafa MA: Controversial risk factors for cholangiocarcinoma. Eur J Gastroenterol Hepatol. 34:338–344. 2022. View Article : Google Scholar : PubMed/NCBI
20	Cholangiocarcinoma Working Group, : Italian clinical practice guidelines on cholangiocarcinoma-part I: Classification, diagnosis and staging. Dig Liver Dis. 52:1282–1293. 2020. View Article : Google Scholar : PubMed/NCBI
21	Chung T and Park YN: Up-to-date pathologic classification and molecular characteristics of intrahepatic cholangiocarcinoma. Front Med (Lausanne). 9:8571402022. View Article : Google Scholar : PubMed/NCBI
22	Forner A, Vidili G, Rengo M, Bujanda L, Ponz-Sarvisé M and Lamarca A: Clinical presentation, diagnosis and staging of cholangiocarcinoma. Liver Int. 39 (Suppl 1):S98–S107. 2019. View Article : Google Scholar
23	Geizhals S and Lipner SR: Review of onychocryptosis: Epidemiology, pathogenesis, risk factors, diagnosis and treatment. Dermatol Online J. 25:13030/qt9985w2n0. 2019. View Article : Google Scholar : PubMed/NCBI
24	Rousselle P and Scoazec JY: Laminin 332 in cancer: When the extracellular matrix turns signals from cell anchorage to cell movement. Semin Cancer Biol. 62:149–165. 2020. View Article : Google Scholar : PubMed/NCBI
25	Tsuruta D, Kobayashi H, Imanishi H, Sugawara K, Ishii M and Jones JCR: Laminin-332-integrin interaction: A target for cancer therapy? Curr Med Chem. 15:1968–1975. 2008. View Article : Google Scholar : PubMed/NCBI
26	Wang H, Cai J, Du S, Wei W and Shen X: LAMC2 modulates the acidity of microenvironments to promote invasion and migration of pancreatic cancer cells via regulating AKT-dependent NHE1 activity. Exp Cell Res. 391:1119842020. View Article : Google Scholar : PubMed/NCBI
27	Zhou YM, Yao YL, Liu W, Shen XM, Shi LJ and Wu L: MicroRNA-134 inhibits tumor stem cell migration and invasion in oral squamous cell carcinomas via downregulation of PI3K-Akt signaling pathway by inhibiting LAMC2 expression. Cancer Biomark. 29:51–67. 2020. View Article : Google Scholar : PubMed/NCBI
28	Liu M, Cai R, Wang T, Yang X, Wang M, Kuang Z, Xie Y, Zhang J and Zheng Y: LAMC2 promotes the proliferation of cancer cells and induce infiltration of macrophages in non-small cell lung cancer. Ann Transl Med. 9:13922021. View Article : Google Scholar : PubMed/NCBI
29	Zhang D, Guo H, Feng W and Qiu H: LAMC2 regulated by microRNA-125a-5p accelerates the progression of ovarian cancer via activating p38 MAPK signalling. Life Sci. 232:1166482019. View Article : Google Scholar : PubMed/NCBI
30	Islam S, Kitagawa T, Baron B, Abiko Y, Chiba I and Kuramitsu Y: ITGA2, LAMB3, and LAMC2 may be the potential therapeutic targets in pancreatic ductal adenocarcinoma: an integrated bioinformatics analysis. Sci Rep. 11:105632021. View Article : Google Scholar : PubMed/NCBI
31	Garg M, Kanojia D, Okamoto R, Jain S, Madan V, Chien W, Sampath A, Ding LW, Xuan M, Said JW, et al: Laminin-5γ-2 (LAMC2) is highly expressed in anaplastic thyroid carcinoma and is associated with tumor progression, migration, and invasion by modulating signaling of EGFR. J Clin Endocrinol Metab. 99:E62–E72. 2014. View Article : Google Scholar : PubMed/NCBI
32	Carpino G, Overi D, Melandro F, Grimaldi A, Cardinale V, Di Matteo S, Mennini G, Rossi M, Alvaro D, Barnaba V, et al: Matrisome analysis of intrahepatic cholangiocarcinoma unveils a peculiar cancer-associated extracellular matrix structure. Clin Proteomics. 16:372019. View Article : Google Scholar : PubMed/NCBI
33	Ye M, Song Y, Pan S, Chu M, Wang ZW and Zhu X: Evolving roles of lysyl oxidase family in tumorigenesis and cancer therapy. Pharmacol Ther. 215:1076332020. View Article : Google Scholar : PubMed/NCBI
34	Lin HY, Li CJ, Yang YL, Huang YH, Hsiau YT and Chu PY: Roles of lysyl oxidase family members in the tumor microenvironment and progression of liver cancer. Int J Mol Sci. 21:97512020. View Article : Google Scholar : PubMed/NCBI
35	Barczyk M, Carracedo S and Gullberg D: Integrins. Cell Tissue Res. 339:269–280. 2010. View Article : Google Scholar : PubMed/NCBI
36	Brown AC, Dysart MM, Clarke KC, Stabenfeldt SE and Barker TH: Integrin α3β1 binding to fibronectin is dependent on the ninth type III repeat. J Biol Chem. 290:25534–25547. 2015. View Article : Google Scholar : PubMed/NCBI
37	Giannelli G, Astigiano S, Antonaci S, Morini M, Barbieri O, Noonan DM and Albini A: Role of the alpha3beta1 and alpha6beta4 integrins in tumor invasion. Clin Exp Metastasis. 19:217–223. 2002. View Article : Google Scholar : PubMed/NCBI
38	Islam K, Thummarati P, Kaewkong P, Sripa B and Suthiphongchai T: Role of laminin and cognate receptors in cholangiocarcinoma cell migration. Cell Adh Migr. 15:152–165. 2021. View Article : Google Scholar : PubMed/NCBI
39	Samaržija I, Dekanić A, Humphries JD, Paradžik M, Stojanović N, Humphries MJ and Ambriović-Ristov A: Integrin crosstalk contributes to the complexity of signalling and unpredictable cancer cell fates. Cancers (Basel). 12:19102020. View Article : Google Scholar : PubMed/NCBI